

AMENDMENT TO THE CLAIMS

This listing of claims will replace all prior versions of claims in the application.

Listing of Claims:

1-145. (Cancelled)

146. (Currently Amended) An isolated cell, wherein said cell expresses Hox 11 and lacks expression of CD45.

147. (Cancelled)

148. (Previously Presented) The cell of claim 146, wherein said cell expresses one or more cell markers selected from the group consisting of: retinoic acid receptor, estrogen receptor, EGF receptor, CD49b, VLA2, CD41, LFA-1, ITB2, CD29, NTC3 receptor, plasminogen receptor, transferrin receptor, TGF receptor, PDGF receptor, thyroid growth hormone receptor, and integrin beta 5.

149. (Previously Presented) The cell of claim 146, wherein said cell is obtained from peripheral blood or tissue of a mammal by a method comprising:

- a) separating cells from said peripheral blood or tissue into a first cell population which predominantly expresses CD45 antigen on the surface of said cells and a second cell population which predominantly does not express CD45 antigen on the surface of said cells; and
- b) selecting said second cell population and further separating Hox11(+) cells from said second cell population to obtain at least one Hox11(+), CD45(-) cell.

150. (Currently Amended) The cell of claim 149, wherein ~~said method further comprises separating said at least one Hox11(+), CD45(-) cell into a third cell population that~~ expresses one of more cell surface markers selected from the group consisting of: retinoic acid receptor,

estrogen receptor, EGF receptor, CD49b, VLA2, CD41, LFA-1, ITB2, CD29, NTC3 receptor, plasminogen receptor, transferrin receptor, TGF receptor, PDGF receptor, thyroid growth hormone receptor, and integrin beta 5, ~~and a fourth cell population which predominantly does not express said cell surface marker.~~

151. (Previously Presented) The cell of claim 146, wherein said cell is obtained from the spleen.

152-157. (Cancelled)